FDA Approves CAR-T Cell Therapy to Treat Adults With Certain Types of Large B-cell Lymphoma
FDA News Release
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma....
Full Text: PDF
LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041
Copyright © 2008 LumiText Publishing. All rights reserved.